Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.


BACKGROUND Collecting duct carcinoma (CDC) is a rare and aggressive subtype of kidney cancer that responds to platinum-based chemotherapy. Recent phase II trials have established enhanced antitumor activity on combining bevacizumab with chemotherapy in patients with metastatic urothelial carcinoma, a tumor that shares many features with CDC. Our aim was to… (More)
DOI: 10.1093/annonc/mdt423


3 Figures and Tables